Skip to main content
SpringerLink
Log in

Eine definitive Strahlentherapie mit einer Kurzzeit Androgendeprivationstherapie von 18 Monaten kann bei Patienten mit lokal begrenztem Prostatakarzinom mit hohen Risikofaktoren gegenüber dem Standard von 28–36 Monaten ausreichend sein

Primary radiotherapy and short androgen deprivation therapy of 18 months may be sufficient in patients with localized prostate cancer with high-risk-factor compared to the standard of 28 to 36 months.

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hanks GE, Pajak TF, Porter A et al (2003) Phase III trialof long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972–3978

    Article  CAS  PubMed  Google Scholar 

  2. Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527

    Article  CAS  PubMed  Google Scholar 

  3. Nabid A, Carrier N, Martin AG et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74:432–441

    Article  CAS  PubMed  Google Scholar 

  4. Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073

    Article  CAS  PubMed  Google Scholar 

  5. Ghadjar P, Wiegel T (2019) Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432–31. Eur Urol 75(3):e61–e62

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Radioonkologie und Strahlentherapie, Charité Universitätsmedizin, Berlin, Deutschland

    Dirk Böhmer

  2. Universitätsklinik für Radiotherapie und Radio-Onkologie, Landeskrankenhaus, Universitätsklinikum, Paracelsus Medizinischen Privatuniversität, Salzburg, Österreich

    Felix Sedlmayer &  Frank Wolf PhD

  3. Abteilung Strahlentherapie, Universitätsklinikum Ulm, Ulm, Deutschland

    Thomas Wiegel

Authors
  1. Dirk Böhmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Sedlmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Wiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank Wolf PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Dirk Böhmer or Felix Sedlmayer.

Ethics declarations

Interessenkonflikt

D. Böhmer, F. Sedlmayer, T. Wiegel und F. Wolf geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Nabid A, Carrier N, Martin AG et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 74(4):432–441. https://doi.org/10.1016/j.eururo.2018.06.018.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Böhmer, D., Sedlmayer, F., Wiegel, T. et al. Eine definitive Strahlentherapie mit einer Kurzzeit Androgendeprivationstherapie von 18 Monaten kann bei Patienten mit lokal begrenztem Prostatakarzinom mit hohen Risikofaktoren gegenüber dem Standard von 28–36 Monaten ausreichend sein. Strahlenther Onkol 195, 764–766 (2019). https://doi.org/10.1007/s00066-019-01470-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01470-5

Search

Navigation